Hypertension Diagnostics, Inc.
HDII · OTC
3/31/2023 | 9/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | – | – | $0 | – |
| % Growth | – | – | – | – |
| Cost of Goods Sold | – | – | $0 | – |
| Gross Profit | – | – | $0 | – |
| % Margin | – | – | – | – |
| R&D Expenses | – | – | $0 | – |
| G&A Expenses | – | – | $0 | – |
| SG&A Expenses | – | – | $1 | – |
| Sales & Mktg Exp. | – | – | $0 | – |
| Other Operating Expenses | – | – | $0 | – |
| Operating Expenses | – | – | $1 | – |
| Operating Income | – | – | -$1 | – |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | – | – | $0 | – |
| Pre-Tax Income | – | – | -$1 | – |
| Tax Expense | – | – | $0 | – |
| Net Income | – | – | -$1 | – |
| % Margin | – | – | – | – |
| EPS | – | – | -0.003 | – |
| % Growth | – | – | – | – |
| EPS Diluted | – | – | -0.003 | – |
| Weighted Avg Shares Out | – | – | 285 | – |
| Weighted Avg Shares Out Dil | – | – | 285 | – |
| Supplemental Information | – | – | – | – |
| Interest Income | – | – | $0 | – |
| Interest Expense | – | – | $0 | – |
| Depreciation & Amortization | – | – | $0 | – |
| EBITDA | – | – | -$1 | – |
| % Margin | – | – | – | – |